TPST - Tempest Therapeutics Inc. Stock Price, Fair Value and News

$3.26+0.23 (+7.59%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TPST Price Action

Last 7 days

1.6%

Last 30 days

-67.5%

Last 90 days

-67.5%

Trailing 12 Months

-71.3%

TPST RSI Chart

TPST Valuation

Market Cap

14.5M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

197.34

EV/EBITDA

-0.22

Price/Free Cashflow

-0.43

TPST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TPST Fundamentals

TPST Revenue

Revenue (TTM)

72.0K

TPST Earnings

Earnings (TTM)

-36.1M

Earnings Growth (Yr)

66.74%

Earnings Growth (Qtr)

55.39%

TPST Profitability

Operating Margin

-494.44%

EBT Margin

-40618.75%

Return on Equity

-568.14%

Return on Assets

-210.49%

Free Cashflow Yield

-230.73%

TPST Investor Care

Shares Dilution (1Y)

32.26%

Diluted EPS (TTM)

-10.05

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	4.0M	2.0M	72.0K	0
2020	0	7.8M	5.9M	0
2018	755.5K	752.5K	5.3M	9.8M
2017	576.0K	471.0K	330.0K	751.5K
2016	567.0K	726.0K	848.0K	659.0K
2015	176.5K	263.0K	349.5K	436.0K
2013	0	0	0	90.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Tempest Therapeutics Inc.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

CEO	Mr. Stephen R. Brady J.D., LLM
WEBSITE	tempesttx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	19

Tempest Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Tempest Therapeutics Inc.? What does TPST stand for in stocks?

TPST is the stock ticker symbol of Tempest Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tempest Therapeutics Inc. (TPST)?

As of Wed Dec 03 2025, market cap of Tempest Therapeutics Inc. is 14.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TPST stock?

You can check TPST's fair value in chart for subscribers.

Is Tempest Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether TPST is over valued or under valued. Whether Tempest Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Tempest Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TPST.

What is Tempest Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TPST's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 197.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TPST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tempest Therapeutics Inc.'s stock?

In the past 10 years, Tempest Therapeutics Inc. has provided -0.598 (multiply by 100 for percentage) rate of return.